BM-1244

• UNSPSC Description:

  BM-1244 (APG-1252-M1) is a potent Bcl-xL/Bcl-2 inhibitor with Kis of 134 and 450 nM for Bcl- xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with an EC50 of 5 nM. (From patent WO2019033119A1)[1].

• Target Antigen:

  Bcl-2 Family

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bm-1244.html

• Smiles:

  O=C(C1CCN(CC[C@@H](NC2=CC=C(S(=O)(NC3=CC=C(N4CCN(C5=CC(F)=CC(C6=C(C7=CC=C(Cl)C=C7)N(C(C)C)C(C)=C6S(=O)(C)=O)=C5)CC4)C=C3)=O)C=C2S(=O)(C(F)(F)F)=O)CSC8=CC=CC=C8)CC1)O

• Molecular Weight:

  1159.79

• References & Citations:

  [1]Jill Hopkins, et al. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells. WO2019033119A1.|[2]Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333(2):336-343.

• Shipping Conditions:

  Room Temperature

• CAS Number:

  1619923-32-8